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What's new? 
• Our study, unlike previous ones, used a standardized clinical interview to measure   
depressive disorders in people with diabetes in 14 countries.  
• Although depressive disorders were frequently present in people with Type 2 diabetes, in 
most cases, these were neither diagnosed nor treated.   
• We have identified particular factors associated with depressive disorders which could be 
considered when developing training for healthcare professionals in ways to identify and 
manage comorbid depression and diabetes. 
 
Abstract 
Aims To assess the prevalence and management of depressive disorders in people with 
Type 2 diabetes in different countries.  
 
Methods People with diabetes aged 18–65 years and treated in outpatient settings were 
recruited in 14 countries and underwent a psychiatric interview. Participants completed the 
Patient Health Questionnaire and the Problem Areas in Diabetes scale. Demographic and 
medical record data were collected. 
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Results A total of 2783 people with Type 2 diabetes (45.3% men, mean duration of diabetes 
8.8 years) participated. Overall, 10.6% were diagnosed with current major depressive 
disorder and 17.0% reported moderate to severe levels of depressive symptomatology 
(Patient Health Questionnaire scores >9). Multivariable analyses showed that, after 
controlling for country, current major depressive disorder was significantly associated with 
gender (women) (P<0.0001), a lower level of education (P<0.05), doing less exercise 
(P<0.01), higher levels of diabetes distress (P<0.0001) and a previous diagnosis of major 
depressive disorder (P<0.0001). The proportion of those with either current major depressive 
disorder or moderate to severe levels of depressive symptomatology who had a diagnosis or 
any treatment for their depression recorded in their medical records was extremely low and 
non-existent in many countries (0–29.6%) 
 
Conclusions Our international study, the largest of this type ever undertaken, shows that 
people with diabetes frequently have depressive disorders and also significant levels of 
depressive symptoms. Our findings indicate that the identification and appropriate care for 
psychological and psychiatric problems is not the norm and suggest a lack of the 
comprehensive approach to diabetes management that is needed to improve clinical 
outcomes. 
 
Introduction 
Worldwide, prevalence rates of both diabetes and mental health problems are increasing 
rapidly [1–4]. Studies indicate that depression and subthreshold depressive states are much 
more common and persistent in people with Type 2 diabetes than in those without [2,5,6]; 
however, in the past, most studies have not used both a psychiatric diagnostic interview and 
a validated diagnosis of Type 2 diabetes [4,6], which might have contributed to the 
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differences in prevalence data reported. The use of a wide range of checklists rather than a 
clinical interview to diagnose depression makes the findings of these studies difficult to 
interpret and compare.  
Depression is associated with less than optimal diabetes self-management, lower levels of 
physical activity and poorer control of diabetes, with a subsequent greater risk of poor 
microvascular and macrovascular outcomes, higher mortality rates and substantially 
increased healthcare costs [7,8]. 
 
There is evidence that depression can be treated successfully with both psychological and 
pharmacological interventions, but under-recognition of mental disorders is a significant 
barrier to successful care [9–11]. Translating the findings of previous studies into clinical 
practice remains a challenge, particularly when recommendations developed in one country 
are offered for use in different cultural and contextual settings, where resources are often 
lacking [11–13]. In addition, depression may overlap with the emotional distress associated 
with having and managing diabetes, leading to additional challenges to the provision of 
appropriate care [14].  
 
This study was conducted under the auspices of the Dialogue on Diabetes and Depression 
(http://diabetesanddepression.org/), an international multidisciplinary group of academics 
and practitioners whose aim is to promote the importance of comorbid diabetes and 
depression, provide education and undertake research in this field. The main objective of the 
present study was to investigate the prevalence and treatment of depression in people with 
Type 2 diabetes in 14 countries. We have conducted a collaborative study using the same 
protocol in these countries which differ in level of socio-economic development, cultural 
setting and level of service development, using standardized ways of identifying depressive 
disorders. The present study is the first of its kind to use both a clinical interview as well as a 
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screening instrument to detect clinical depression and depressive symptoms, and to also 
record the diagnoses of diabetes complications contained in medical records kept by leading 
centres of care for people with diabetes.   
 
Methods 
A full description of the protocol used in the present study is provided in our earlier paper 
[15].  In brief, between September 2013 and May 2015 a sample of consecutive outpatient 
clinic attendees with Type 2 diabetes at each of the study sites was invited to participate in 
the study, with the aim of including 200 people with Type 2 diabetes in each country. Site 
investigators, recruited from leading centres of excellence in each country, included at least 
one psychiatrist and endocrinologist for each country. The treating physician/diabetologist in 
the diabetes clinic invited individuals to participate in the study. Diabetes clinics were based 
in either secondary or tertiary care centres, depending on the facilities available in each 
country. Written informed consent was obtained from all participants.   
 
Inclusion/exclusion criteria  
Eligible study participants were adults (aged 18–65 years) with Type 2 diabetes [15] 
diagnosed at least 12 months before the point of contact attending their diabetes outpatient 
facilities. Individuals were excluded if they had been diagnosed with Type 2 diabetes for <12 
months as it is usual to experience a period of adjustment when first diagnosed. Other 
exclusion criteria were: diagnosis of Type 1 diabetes; inability to complete the survey tools 
because of communication or cognitive difficulties; and any life-threatening or serious 
conditions (e.g. cancer, stroke in the last 6 months). Those currently admitted or planning an 
admission for inpatient care to a hospital (unless admitted for diabetes self-management) 
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were excluded because this group may have been receiving more intensive or different 
treatment for their diabetes and so were less comparable with those not admitted. Women 
who were pregnant or had given birth in the last 6 months were also excluded, as were those 
who had received a clinical diagnosis of dependency on alcohol or other substance (not 
tobacco) or a diagnosis of schizophrenia.  
 
Prior to interview the site investigators completed an information form for each eligible 
individual. This form included information from medical records, such as age, duration of 
diabetes, family history of diabetes and presence/history of diabetes complications. The 
latter included cardiovascular disease, retinopathy, peripheral neuropathy, peripheral 
vascular disease and renal disease and associated disorders. Most recent measurements of 
blood pressure, HbA1c, height and weight were also recorded; however, because the timing 
of HbA1c measurements varied in terms of proximity to the clinical interviews they were not 
used in the data analysis. A diagnosis of current major depressive disorder (MDD) was 
made at interview so that the proximity of clinical records did not differ. Any documentation 
of prescribed medications for depression or other mental health problem in each individual’s 
medical records was noted, as was any documented diagnosis or treatment of any 
psychiatric condition. Participants were asked if they lived in what they considered to be a 
rural or an urban area, and reported their highest level of education (defined as no formal, 
some/completed primary, some/completed secondary school, or higher education, which 
was defined as any college, postgraduate or professional training). Marital status was 
defined as married/cohabiting vs being single/widowed/divorced which, for our analyses, 
was dichotomized into living alone vs not living alone. Participants were also asked if they 
considered that they had a regular income.  
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Each participant was asked to complete the Patient Health Questionnaire (PHQ-9) and the 
Problem Areas in Diabetes (PAID) scale. The PHQ-9 consists of nine items on a four-point 
Likert-type scale [17]. It has good sensitivity and specificity with regard to identifying cases 
of depression as well as being sensitive to change over time, and has been used in a number 
of different countries [17]. Moderate/severe depressive symptomatology was defined as 
PHQ-9 scores > 9, as this was a research study rather than clinical practice, in which a 
significant level of symptoms would usually be considered to be PHQ-9 scores >15 [11]. The 
PAID scale is a 20-item questionnaire which measures the extent of diabetes-related 
emotional distress [18]. Items include ‘feeling overwhelmed with your diabetes’ and ‘feelings 
of guilt or anxiety when you get off track with your diabetes management’. Moderate/severe 
levels of diabetes-related distress are defined as scores (standardized to 100) >40 [18]. All 
questionnaires were completed using standard self-complete methods in the appropriate 
language, or assisted one-to-one collection, with the questions read out by the researcher and 
answered by the participant. Where no existing translation/cultural adaption of the 
questionnaire was available it was adapted using standard forward/back translation 
procedures. In addition, each country’s investigators ensured the questionnaires were 
culturally applicable through their development over several iterative stages, involving 
discussion and testing by a range of healthcare professionals and people with Type 2 diabetes 
and focusing on the meaning of terms as well as language.  
  
A psychiatric interview was subsequently conducted by a trained interviewer using the Mini 
International Neuropsychiatric Interview (V5 or V6 depending on current psychiatric practice 
at the study site) [19]. The Mini International Neuropsychiatric Interview has been widely 
used in a range of different populations, including those with serious illness, and in 
community surveys, and is a reliable diagnostic tool according to Diagnostic and Statistical 
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Manual of Mental Disorders 5th edition (DSM-V) criteria [20] as long as appropriate training is 
given. Individuals diagnosed with depression (or other psychiatric disorders such as anxiety 
disorders) were advised to consult their physician for further assessment and treatment. If 
any individual indicated suicidality (question 9 on the PHQ-9) the psychiatrist conducting the 
clinical interview initiated immediate appropriate care. Where required, all those collecting 
the data were trained in the use of the Mini International Neuropsychiatric Interview by the 
relevant senior staff. Depression was defined at interview as a current (within 2 weeks) 
diagnosis of MDD in accordance with the criteria given in the International Classification of 
Diseases 10 classification (and the corresponding criteria of MDDs in the DSM-IV). Previous 
MDD, lifetime (i.e. either current or previous MDD) and recurrent MDD (i.e. with both current 
and previous MDD) were also diagnosed at interview. 
 
Ethical approval 
Prior to commencing the study, ethical approval was obtained in all study settings. Ethical 
approval also was obtained from the Open University, UK, where the data were stored for 
analysis. 
 
Statistical analysis 
SPSS [23] was used to analyse the data. Descriptive statistics are reported, along with 
univariate (t-test, chi-squared test, Wilcoxon rank-sum test) analyses to examine the 
differences between those with and without current MDD and those with PHQ-9 scores 
above and below the threshold for moderate/severe depressive symptomatology (threshold 
>9). Missing data are indicated in the relevant tables for each country. Fewer than 3% of our 
data were missing, and could be regarded as missing completely at random for the predictors. 
After performing Little’s missing-completely-at-random test (chi-squared =30.26, P=0.991), 
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we imputed these missing data using hotdeck imputations [22] where a random draw from a 
subset of comparable cases by country, sex and education is imputed using the Bayesian 
bootstrap method of Rubin and Schenker [23]. 
  
We then used multivariable generalized estimating equations [24] with a binary logistic 
regression to examine risk factors for current MDD and PHQ-9 score >9 while controlling for 
country-specific effects. Only the variables that were significantly associated with MDD or 
moderate/severe depressive symptomatology in the bivariate analysis were included. 
Estimations were calculated using an exchangeable working correlation structure. Predictor 
variables included demographic, anthropometric and diabetes-specific variables, and 
psychosocial variables. Having two models enabled us to compare the results for current 
MDD with moderate/severe depressive symptomatology.   
 
Results 
Response rates  
A total of 2783 individuals with Type 2 diabetes agreed to participate in the study, a response 
rate of 92.3%. Response rates differed according to country of study, ranging from 64.7% 
(Ukraine) to 100% in Uganda, Mexico and India. Women were more likely to participate 
than men (93.7 vs 90.8%; P=0.003). The main reason for not participating was being too 
busy to remain in the clinic to undergo the examination. Participants were younger than non-
participants (53.54 ± 9.20 vs 55.26 ± 10.80 years; P=0.010), but diabetes duration was not 
significantly different between those who agreed to participate and those who did not. Those 
without a regular income were more likely to participate than those who did (97.1 vs 92.6%; 
P<0.0001).  
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Table 1 provides the overall details of the participants; country-specific information is 
provided in Tables S1 and S2. Roughly equal proportions of men and women participated 
and the majority of participants (72.7%) were married or cohabiting. Only 7.4% had no 
formal education, 30.8% had a higher education level, and 16.8% had no regular income. In 
total, 50.8% of participants had one or more complications, with retinopathy and neuropathy 
being the most commonly diagnosed. 
  
Overall, 10.6% of participants were diagnosed with current MDD at interview (Table 1) and 
16.6% had lifetime MDD. Rates of current MDD differed widely among countries, ranging 
from 1% (Uganda) to 29.9% (Bangladesh; Table S2). Rates of lifetime MDD ranged from 
1% (Uganda) to 32.5% (Russia). Similarly, the proportion of participants with a previous 
MDD was 10.5%, ranging from 0.5% (Uganda) to 21.0% (Russia). Recurrent MDD rates 
were much lower than this (4.6%; ranging from 0% in Uganda/Ukraine to 17.0% in 
Bangladesh). Nearly half (43.6%) of those with current MDD had a previous diagnosis of 
depression.  
The proportion of individuals reporting moderate/severe depressive symptomatology (PHQ-9 
scores >9) was higher than the current MDD diagnosis rate (17.0%; ranging from 1% in 
Uganda to 32.5% in Bangladesh). The majority (72.5%) of those with current MDD had 
moderate/severe depressive symptomatology. Overall, 12.8% of participants reported 
moderate/severe (scores >40) levels of diabetes-related distress (PAID scores).  
 
Bivariate associations  
Those with current MDD were significantly more likely to be diagnosed with panic disorder 
than those without current MDD (14.7 vs 2.7; chi-squared (1) = 100.11, P<0.0001). Similarly 
those with current MDD were significantly more likely to have post-traumatic stress disorder 
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(7.2 vs 3.1%; chi-squared (1) = 12.69, P<0.0001) or generalized anxiety disorder (22.9 vs 
4.6%; chi-squared(1) = 144.8, P<0.0001). There were also significant differences in the 
proportion of people with and without current MDD who also received a diagnosis of social 
anxiety disorder (8.9 vs 1.9%, respectively; chi-squared(1) = 51.07, P<0.0001) or psychotic 
disorder (1.0 vs 0.2%, respectively; chi-squared(1) = 5.0, P<0.05).  
 
Those with moderate/severe depressive symptomatology were significantly more likely to be 
diagnosed with panic disorder than those with low scores (12.5 vs 2.2%; chi-squared (1) = 
108.69, P<0.0001). Similarly those with moderate/severe depressive symptomatology were 
significantly more likely to have post-traumatic stress disorder (8.0 vs 2.4%; chi-squared (1) 
= 37.12, P<0.0001) or generalised anxiety disorder than those without (17.0 vs 4.4%; chi-
squared (1) = 100.71, P<0.0001). There were also significant differences in the proportion of 
people with or without moderate/severe depressive symptomatology who also received a 
diagnosis of social anxiety disorder (5.4 vs 2.1%; chi-squared (1) = 16.36, P<0.0001) or 
psychotic disorder (1.1 vs 0.2%; chi-squared (1) = 9.51, P<0.01).  
        
Overall, those with current MDD were significantly more likely to be women (women, 
73.1% vs men, 26.9%; chi-squared (1) = 45.07, P<0.0001). Age and smoking preferences did 
not significantly differ between those with or without current MDD but longer duration of 
diabetes (z = –4.6, Prob > |z| < 0.0001), less exercise (z = 4.11, Prob > |z| < 0.0001), and 
lower education level (z = 2.6, Prob > |z| < 0.05) did. Participants who were on insulin were 
twice as likely to have a current MDD diagnosis than those not taking insulin (14.5 vs 7.8%; 
chi-squared (1) =32.7, P<0.0001), and had a greater BMI than those without current MDD 
(29.7 ±6.6 vs 28.8 ± 6.0 kg/m2; P<0.05). 
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Those with current MDD were significantly less likely to be married or cohabiting than those 
without current MDD (67.4 vs 73.3%; chi-squared (1) = 4.69, P<0.05), were more likely to 
report a lack of regular income (22.5 vs 16.5%; chi-squared (1) = 6.5, P<0.01) and were 
significantly more likely to be living in an urban rather than rural location (90.8 vs 84.4%; 
chi-squared (1) = 8.5, P<0.01). 
 
Those with current MDD were significantly more likely to have a diagnosis of past MDD 
than those without current MDD (43.7 vs 6.8%; chi-squared (1) = 372.9, P<0.001). 
Participants with current MDD were more likely to report moderate/severe levels of diabetes-
related distress than those without current MDD (34.0 vs 10.7%; chi-squared (1) =125.5, 
P<0.001). Overall, those with current MDD were significantly more likely to have 
nephropathy (16.0 vs 9.8%; chi-squared (1) =10.23, P<0.01), neuropathy (47.2 vs 24.3%; 
chi-squared (1) = 69.4; P<0.0001) and stroke (9.6 vs 6.1%; chi-squared (1) =5.15, P=0.05). 
The proportion of those individuals with current MDD significantly increased with the 
number of complications they had, from 6.5% of those without any complications to 15.5% 
of those with five or more complications (z = –7.3, Prob > |z| < 0.001). 
 
Those with moderate/severe depressive symptomatology were more likely to be women 
(69.7%; chi-squared (1) = 51.1; P<0.0001). Age and smoking preferences did not 
significantly differ between those with or without moderate/severe depressive 
symptomatology, but longer duration of diabetes (z=-4.7 Prob>|z|<0.0001), less exercise (z = 
5.4, Prob > |z| < 0.0001), and less education (z = 4.9, Prob > |z| < 0.0001) did significantly 
differ between those with and without moderate/severe depressive symptomatology. Those 
taking insulin were significantly more likely to have moderate/severe depressive 
symptomatology than those not taking insulin (21.6 vs 13.7%, respectively; chi-squared (1) = 
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29.4, P<0.0001). In addition, BMI was significantly greater in those with moderate/severe 
depressive symptomatology (29.6 ± 6.5 vs 28.7 ± 6.0, P<0.01).Those with moderate/severe 
depressive symptomatology were significantly less likely to be married or cohabiting than 
those without current MDD (68.0 vs 73.9%; chi-squared (1) = 6.8, P<0.01) and were more 
likely to report having no regular income (28.5 vs 14.9%; chi-squared (1) = 50.9, P<0.0001). 
There was no significant association between the likelihood of living in an urban vs a rural 
area according to PHQ-9 scores. Those with moderate/severe depressive symptomatology 
were much more likely to have a diagnosis of previous MDD than those with lower scores 
(46.1 vs 13.6%; chi-squared (1) = 194.0, P<0.0001). Participants with moderate/severe 
depressive symptomatology were more likely to report moderate/severe levels of diabetes-
related distress than those without (35.8 vs 8.4%; chi-squared (1) = 255.9, P<0.0001).  
 
Overall, those with moderate/severe depressive symptomatology were significantly more 
likely to have nephropathy (13.5 vs 9.9%; chi-squared (1) = 5.2, P<0.05) and neuropathy 
(43.5 vs 23.1%; chi-squared (1) = 80.9, P<0.0001) than those without. The proportion of 
those with moderate/severe depressive symptomatology significantly increased with the 
number of complications they had, from 12.0% of those without any complications to 23.6% 
of those with five or more complications Z=–7.5 (Prob> |z| <0.0001).  
 
Multivariable results 
As shown in Table 2, significant predictors of current MDD (controlling for country) were 
female gender, lower education level, insulin treatment, higher PAID scores, previous MDD, 
and less exercise. For current MDD, women had a statistically significant odds ratio of 1.96 
vs men. Compared with participants who did not regularly exercise, those who exercised 
daily had a significantly lower risk of current MDD (odds ratio 0.88). Compared with PAID 
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scores ≤40, participants with a score >40 had significantly higher odds of current MDD 
(2.88), while people with previous MDD had a statistically significant odds ratio of 7.46 of 
occurrence of current MDD compared with those without previous MDD. Higher education 
level significantly decreased the odds of MDD vs no education, whereas primary and 
secondary levels did not.  
Similar associations were found in a separate model examining the variables associated 
with moderate/severe depressive symptomatology, with the exceptions of insulin treatment 
(only significant for the MDD model) and having fewer diabetes complications, which 
significantly decreased the odds of moderate/severe depressive symptomatology. Lack of a 
regular income increased the odds of having moderate/severe depressive symptomatology.  
Between 0 and 37.5% of those with current MDD had any documentation of medications and 
between 0 and 20% had a diagnosis of a psychiatric disorder (including MDD) in their 
medical records (Table 3). Similarly, between 0 and 66.7% (two-thirds of cases) and 0 and 
28.6% of those with recurrent MDD had either documentation of medications or a diagnosis 
in their medical records. Rates were similar in those with moderate/severe depressive 
symptomatology (Table 3). Even in those countries where there was some evidence of 
documented diagnoses/medications, very low rates were observed; for example, in Italy 
three out of eight people with current MDD had medications documented and only one in 
eight had a diagnosis documented. There was no significant difference in recording of 
medications between those with current (and no previous or recurrent) vs those with 
recurrent MDD (36.4 vs 63.6%; chi-squared (1) = 1.3, P=0.25); however, those with 
recurrent MDD were significantly more likely to have a diagnosis of depression recorded in 
their medical records than those with current MDD (75.0 vs 25%; chi-squared (1) = 5.6, 
P<0.05). 
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Discussion  
We observed substantial rates of mental health problems in the present study, with 10.6% of 
participants receiving a clinical diagnosis of current MDD and 17% reporting 
moderate/severe depressive symptomatology as measured by the PHQ-9. Furthermore, 
16.6% had lifetime but only 4.6% had recurrent depression. Worryingly, the proportion of 
those with current MDD who had a diagnosis or treatment for their depression noted in their 
medical records was for the most part extremely low, and non-existent in many countries, 
suggesting a lack of joined-up care for those with comorbid diabetes and depression. Fewer 
than half (45.3%) of those with moderate/severe depressive symptomatology were 
diagnosed with current MDD at interview, suggesting that the former questionnaire may well 
identify individuals as being depressed who do not meet the criteria for diagnosis, or the 
perceptions of people with diabetes as to their difficulties in dealing with their diabetes.  
 
The present INTERPRET-DD study was a collaborative study of the prevalence of 
depressive states that used the same protocol and was carried out at the same time in 14 
different countries. It included almost 3000 people with a clinical diagnosis of Type 2 
diabetes [15].  Overall our response rate was extremely high, most likely because of the 
place of recruitment (diabetes clinic) and the person doing the recruiting (the treating 
physician). However, the study has a number of limitations. Although the total number of 
study participants reached almost 3000, numbers in some countries were lower than in 
others and there were too few cases of MDD in many of the countries, which made it difficult 
to perform site-specific analyses, for example, comparing the socio-economic differences 
among countries. We cannot say for certain, therefore, that the different rates were not 
attributable to between-country characteristics. The data collected from participants’ medical 
records were extensive, but, although participants were recruited at their usual clinic 
appointment, some information may have been missed when records were kept in more 
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than one place. The study was undertaken in specialist clinics where the case mix may be 
different from the wider diabetes population, therefore, there may be an overestimate of the 
risk of depression. Some countries may have less extensive medical records than others or 
may be less likely to document a diagnosis of a condition (either physical or mental) that in 
many cultures is often perceived as stigmatized and so is less likely to be acknowledged. 
Identifying symptoms of depression or distress using tools that were originally developed in 
Europe/North America may also be problematic despite their extensive development for use 
in other cultures [25]; for example, symptoms of distress may seem to be associated with the 
personal experience of physical illness and so not reported or identified as depression. Our 
results show that there is a significant difference between both diabetes distress (PAID 
score) and PHQ-9 scores according to the country of the study (Manova P<0.0001; Table 
S2, footnote). This may be attributable to different cultural experiences of symptoms; for 
example, in Uganda low rates may be related to the moderating effect of particular cultural 
practices where, when a person falls ill, the whole family and community are involved in 
care, in contrast to other countries where the focus is on the individual. 
There may be different interpretations with regard to the variables ‘regular income’ and ‘rural 
area’, which may have limited our analysis when we included these variables. Nevertheless, 
we would argue that it is the participants’ understanding of their life situation that is 
important, as is their reporting of whether they feel depressed or anxious about their 
diabetes.  
 
In spite of the above-mentioned caveats, the major advantages of the present study are the 
large sample in 14 countries, which involved a clinical diagnosis of depression by specially 
trained interviewers using the same methods rather than solely relying on checklists to 
record depressive symptoms, and the use of standard methods for translating any 
questionnaires that had not been translated and validated before. The study took place in 
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each participant’s usual place of care, where opportunities for identifying symptoms of 
depression and/or distress may exist.  
   
In the present study, we confirmed previous findings from other countries in Europe that 
depressive disorders are common in people with diabetes. We identified differences in the 
prevalence of depressive symptoms, as well as the clinical diagnosis of depression among 
the countries. This may reflect differences in the acceptance/stigma (or indeed denial) of 
acknowledging symptoms of psychological and emotional distress in different cultural 
groups.  The results of the present study showing significant multivariable associations of 
current MDD diagnosis with demographic and psychosocial variables are generally 
consistent with those of other cross-sectional studies carried out in the UK and USA using 
self-reported symptoms of depression. Although a somewhat similar pattern emerged when 
using a moderate/severe PHQ-9 score as the dependent variable, stronger associations 
were observed with income and complications, reflecting the importance of diabetes-related 
factors and wider life issues [26]. Although measures differ across studies, depression, 
whether assessed by self-reported symptoms or by diagnostic interviews, has been found to 
be strongly associated with gender, lower education level [26,27], physical inactivity [28] and 
previous depression [27]. Consistent with other studies, we found significant links between 
MDD and diabetes complications, although the latter was a stronger predictor in the 
moderate/severe depressive symptomatology model [29,30]. Mean age and BMI in the 
present study were comparable with data from other multinational studies such as the 
DAWN2 study [31];  however, the percentage of people treated with insulin was higher in the 
present study than in the DAWN2 study, which may be explained by the fact that participants 
in the latter study were stratified by type of treatment, while the present study only included 
participants from secondary care, who are more likely to be treated with insulin.     
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Interestingly, we found that diabetes-related distress was a significant independent predictor 
of MDD and also moderate/severe depressive symptomatology. Recent research has shown 
that, although depressive symptoms and distress overlap to some extent, they are not 
interchangeable [16,32]. While it is sometimes difficult to distinguish between them, the 
present study indicates that the two measures assess distinct constructs, with many people 
reporting high levels of depressive symptoms who did not report significant levels of 
diabetes-related emotional distress. 
 
There are now a number of national and international guidelines for supporting people with 
diabetes and mental health difficulties, and research into the psycho-emotional 
consequences of diabetes has been increasing in recent years [4,5,9,31–34]; however, 
although it has been acknowledged that mental disorders massively contribute to the 
numbers of years lost through disability [35], there remain barriers to access of services that 
would improve mental health, particularly in countries where resources are often 
unavailable. The situation is even worse when it comes to the comorbidity of mental and 
physical disorders, which is undoubtedly one of the major problems with regard to 
healthcare in the 21st century [35]. Based on our observations in the present study, the 
feasibility of using different therapies for the treatment of comorbid diabetes and depression 
rests on a number of factors. In particular the range of available treatments within each local 
context [15], the awareness of those caring for people with these two conditions, the 
acceptance of the need and preferences for treatment and the demonstrability of successful 
outcomes are all important factors that influence the applicability of different therapies in 
different settings. The countries involved in the INTERPRET-DD study have found that multi-
disciplinary care and improved liaison between different specialties are key to improving 
care, but many countries still do not have national guidelines which can be implemented 
locally.  
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The present study draws attention to the magnitude and significance of comorbid depressive 
disorders and diabetes, both of which are of growing prevalence and public health 
significance.  The burden of complications in association with MDD has important 
implications for both the individual with diabetes and also health services provision. Our 
finding that a previous MDD was predictive of current MDD underscores the need for better 
understanding of and monitoring and treatment for mental illness; however, mental health 
care is not likely to receive any attention until what are seen as more pressing needs for 
physical care are met. Although we determined the broad range of treatments available in 
each country before commencing data collection, we did not recorded any non-
pharmacological treatments at baseline. Our follow-up study will rectify this, however, as the 
treatment journey for every person diagnosed at baseline will be recorded. We have found 
an almost non-existent recording of any symptoms of/medications prescribed for depression 
in the medical records of those to whom we gave a clinical diagnosis of MDD. This may be 
for a number of reasons, which require further investigation.  Our research supports previous 
studies in which low recognition rates have also been observed [36,37]. Awareness of the 
importance of mental health problems is a first step towards improving care, but improved 
service provision is of major importance. Although better screening could be recommended, 
serious consideration must be given to the ethical quandary of identifying those who require 
psychological support where there is no treatment available to offer. Healthcare 
professionals may understandably be reluctant to make a diagnosis of depression (or indeed 
any other psychological problem) if care is not available.   
Longitudinal studies are vital if we are to understand the impact of depression and other 
mental health problems on diabetes, its management and the development of other 
comorbidities. 
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Table 1  Profile of INTERPRET-DD participants (total sample) 
Demographic profile  
Men, n (%) 1261 (45.3) 
Age, years 54.1 (9.1) 5 
Married/co-habiting, n (%) 2019 (72.5)5 
Urban location, n (%) 2372 (85.4)4 
Higher education, n (%) 856 (30.8)1 
No regular income, n (%) 468 (16.8)2 
Current smoker, n (%) 374 (13.5) 
Exercise (at least weekly) , n (%) 1643 (59.0)18 
  
Diabetes specific and anthropometric 
profile 
 
Diabetes duration, years 8.8 (6.7) 78 
BMI, kg/m2 28.86 (6.07) 37 
Insulin use, n (%) 1164 (41.8) 9 
Number of complications, n (%)  
0 1369 (49.2) 
1 735 (26.4) 
2 353 (12.7) 
3 178 (6.4) 
4 90 (3.2) 
≥5 58 (2.1) 
  
Psychological profile  
Current MDD  294 (10.6)          
Previous MDD 297 10.7) 6       
Recurrent MDD* 128 (4.6) 6   
Lifetime MDD* 463 (16.6) 5 
Moderate-severe depressive symptomatology 
(PHQ-9 >9) 
466 (17.0) 48 
PAID (diabetes distress) score >40 352 (12.8) 52 
MDD, major depressive disorder; PAID, Problem Areas in Diabetes. 
Values are mean (sd) except where indicated.  
*Lifetime MDD: current or previous MDD; recurrent MDD: both current and previous MDD.  
Numbers in italics are the number of participants with missing data for that variable. 
Country-specific rates are shown in Table S2. 
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Table 2 Demographic, anthropometric, diabetes-specific, lifestyle and psychosocial 
predictors of current major depressive disorder and moderate/severe depressive 
symptomatology, determined by generalised estimating equation logistic regression 
Variables Current MDD Moderate/severe depressive 
symptomatology (PHQ-9 score >9) 
 
 Odds ratio 95% CI P Odds ratio  95% CI P 
Sex female vs male* 1.96 1.54; 2.51 <0.0001 1.70 
 
1.43; 2.02 <0.0001
Marital status  
not married vs 
married* 
0.97 
 
0.76; 1.24 0.83 1.00 
 
0.88; 1.14 0.99 
Education level 0.81 
 
0.68; 0.96 0.01 0.73 
 
0.64; 0.83 <0.0001
Regular family income 
no vs yes* 
1.28 
 
0.94; 1.74 0.12 1.99 
 
1.43; 2.77 <0.0001
Location of residence 
rural vs urban* 
0.69 
 
0.45; 1.05 0.08    
BMI 1.00 
 
0.98; 1.02 0.96 1.01 
 
0.98; 1.03 0.70 
Duration of diabetes 1.03 
 
0.98; 1.03 0.82 1.01 
 
0.997; 1.03 0.11 
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Insulin treatment 
no vs yes* 
0.77 
 
0.61; 0.97 0.03 0.88 
 
0.67; 1.15 0.36 
Number of diabetes 
complications  
1.18 
 
0.98; 1.43 0.08 1.17 
 
1.00; 1.35 0.04
Exercise level 0.88 
 
0.78; 0.98 0.02 0.88 
 
0.82; 0.94 <0.0001
PAID score 
high ≥40 vs low<40* 
2.88 
 
1.99; 4.17 <0.0001 5.59 
 
3.54; 8.85 <0.0001
Previous MDD 
yes vs no*  
7.46 4.26; 12.99 <0.0001 3.97 2.68; 5.88 <0.0001
MDD, major depressive disorder; PAID, Problem Areas in Diabetes; PHQ-9, Patient Health Questionnaire. 
*Denotes reference category;  
Comparison of the two models to test if the odds ratio for one model falls outside the CI for the other model where the 
variables are significant in at least one model: the model is not significantly different except for previous MDD, PAID scores 
(significant in both the models but had odds ratio higher in one model than the CI) and family income (significantly 
associated only with moderate-severe depressive symptomatology with higher odds ratio for the moderate-severe depressive 
symptomatology model than the CIs of the first model). 
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Table 3 Number of recorded medications for depression or diagnosis of depression in those 
with diagnosed MDD (current and recurrent) and moderate/severe depressive 
symptomatology at interview 
 Current MDD 
(diagnosed at 
interview) 
Recurrent MDD 
(diagnosed at interview) 
Moderate-severe 
depressive 
symptomatology (PHQ-9 
score >9)  
Country  Number with 
medications 
documented 
Number 
with a 
documente
d diagnosis  
Number 
with 
medications 
documente
d 
Number 
with a 
documente
d diagnosis  
Number 
with 
medications 
documente
d 
Number  
with a 
documente
d diagnosis  
Argentina 0/16 0/16 0/10 2/10 0/18 2/18 
Banglades
h 
0/58 0/58 0/33 0/33 0/63 0/63 
China  0/42 3/42 0/7 2/7 0/56 2/56 
Germany 0/5 1/5 0/4 1/4 1/19 2/19 
India 0/4 0/4 0/1 0/1 0/31 5/31 
Italy 3/8 1/8 2/3 1/3 7/26 7/26 
Kenya 0/5 0/5 0/0 0/0 2/22 0/22 
Mexico 2/37 3/37 2/18 1/18 2/61 4/61 
Pakistan 1/24 0/24 0/5 0/5 0/41 1/41 
Poland 0/32 4/32 0/22 4/22 0/30 3/30 
Russia 1/34 0/34 0/11 0/11 0/47 0/47 
Serbia 4/19 2/19 3/13 1/13 4/27 3/27 
Uganda 0/2 0/2 0/1 0/1 0/2 0/2 
Ukraine 0/8 0/8 0/0 0/0 0/23 0/23 
TOTAL 11/294  14/294 7/128 12/128 16/466 29/466 
MDD, major depressive disorder; PHQ-9, Patient Health Questionnaire. 
Medications documented: any documentation of prescribing medications for depression or other mental health 
problem in individual participant’s medical records. 
Documented diagnosis: any psychiatric condition reported as diagnosed or treated in individual participant’s 
medical records. 
 
